NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

Medpace Holdings, Inc. (MEDP) Stock Analysis

Medpace Holdings, Inc. (MEDP) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MEDP

$662.48

+$40.05 (+6.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MEDP with… →

MEDP Key Statistics

As of Oct 21, 2026
Trading
Open
$614.98
Previous Close
$622.43
Day's Range
614.98–666.34
52-Week Range
373.00–677.90
Volume
1.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.18
Valuation
Market Cap
$18.49B
P/E Ratio
38.90
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
34.30
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.96
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.65
EPS (ttm)Profit attributable to each share over the last twelve months.
17.03
Financials (FY)
Revenue (FY)
$2.53B+19.97%
Net Income (FY)
$451.12M+11.56%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.67%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.91M
1-Year Return
+21.41%
Dividend and dates
Earnings Date
October 21, 2026
Avg Volume
274.02K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MEDP closed at $662.48, +21.41% over 1 year.

Medpace Holdings, Inc. (MEDP) has a market capitalization of $18.49B.

In fiscal 2025, MEDP reported revenue of $2.53B.

MEDP Stock Return by Calendar Year

Medpace Holdings, Inc. (MEDP) 10-year return: what $10,000 became

1 year
$10,000 $12,141
+21.41%
5 years
$10,000 $35,611
+256.11%
10 years
$10,000 $211,655
+2,016.55%

If you had invested $10,000 in Medpace Holdings, Inc. (MEDP) 10 years ago, at the close on October 21, 2016, it would have been worth $211,655 at the close on October 21, 2026: +2,016.55% in total, +35.69% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+17.95%
2025+69.05%
2024+8.38%
2023+44.31%
2022−2.40%
2021+56.35%
2020+65.60%
2019+58.81%
2018+45.97%
2017+0.53%
2016 (partial year)+29.79%

As of October 21, 2026.

MEDP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.53B$451.12M17.8%
2024$2.11B$404.39M19.2%
2023$1.89B$282.81M15.0%
2022$1.46B$245.37M16.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.53B$760.62M$534.94M$451.12M17.8%
2024$2.11B$656.31M$446.87M$404.39M19.2%
2023$1.89B$524.51M$336.83M$282.81M15.0%
2022$1.46B$432.44M$278.70M$245.37M16.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MEDP Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricMEDPDiagnostics & Research medianvs median
P/E38.9037.593% above
P/S ratio6.655.2327% above
Profit margin17.67%−0.93%18.6 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Medpace Holdings, Inc. (MEDP) carries a market capitalisation of $18.49B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 6,500 employees.

The 52-week range on file runs from $373.00 to $677.90. MEDP last closed at $662.48 on October 21, 2026. That is +$40.05 (+6.43%) against the previous close. The latest close sits 77.61% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.53B. That is +19.97% against the prior fiscal year, when revenue was $2.11B. The same year closed with net income of $451.12M. That is +11.56% against the prior fiscal year. Profit margin runs at 17.67%. That is 18.6 percentage points above the Diagnostics & Research median of −0.93%. Trailing earnings per share are 17.03.

Across the 4 fiscal years on file, revenue moves from $1.46B in 2022 to $2.53B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 38.9 times earnings. That is 3.5% above the Diagnostics & Research median of 37.59. On forward earnings the ratio is 34.3. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.96. The price-to-sales ratio is 6.65. On price-to-sales that is 27.15% above the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +21.41%. Measured over 10 years, that is +35.69% a year compounded. The reported beta is 1.18. Daily returns over the trailing 10 years annualize to a volatility of 49.71%.

Growth & Income

The record shows no dividend for MEDP.

So far in 2026 the total return is +17.95%. The strongest complete calendar year on file is 2025 at +69.05%; the weakest is 2022 at −2.40%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

Medpace Holdings, Inc. (MEDP) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Medpace Holdings, Inc. MEDP $18.49B 38.9
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Medpace Holdings, Inc. trades at a P/E of 38.9.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Visit website →